Search This Blog

Thursday, November 5, 2026

Precision BioSciences no safety concerns, OKs dosing of additional patients in Phase 1/2 DMD trial

 


  • Independent DSMB assessment based on safety data from the first PBGENE-DMD patient in the Phase 1/2 FUNCTION-DMD trial.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)